18.04.2021, 2353 Zeichen

Frequentis: Iarnród Éireann, Irish Rail, has been implementing the Frequentis fixed terminal railway dispatcher terminal to enhance rail operations across Ireland. The new digital platform provides increased situational awareness for the controller and geo redundancy, providing a modern and future proof solution as an upgrade to the existing Frequentis system, installed in 2013. The Frequentis FTS 3020 is used by many of the world’s major railways as a component of the operational communication system. The new platform allows for more information to be displayed at a glance and on larger HD screens. Around 45 terminals were delivered as part of the project and the system acceptance took place at Dublin’s most important rail and urban transport station, Connolly. Frequentis is an international supplier of communication and information systems for control centres with safety-critical tasks.
Frequentis: weekly performance: 3.15%

Marinomed: Marinomed Biotech AG, an Austrian science-based biotech company with globally marketed therapeutics derived from innovative proprietary technology platforms, today reported strong results for the fiscal year ending 31 December 2020. The company closed the year with an 32 % increase in revenues to Euro 8.12 mn (2019: Euro 6.14 mn). Investments in research and development increased by almost 25 % in 2020 at € 5.94 m (2019: € 4.78 m), of which the largest part is attributable to clinical development. The operating loss (EBIT) of Euro 5.82 m improved compared to 2019 at Euro 6.21 mn. The total loss for 2020 was reduced to Euro 6.01 mn from Euro 7.22 mn in 2019. Pascal Schmidt, Marinomed’s CFO, said: “We are very pleased to report a strong 2020. We saw a significant increase in Carragelose demand and optimized our supply chain early in the year to eliminate supply bottlenecks. This allowed us to realize record revenues. Based on this, we improved our operating results despite significantly increased spending in our R&D programs. As a science-based company, research and development is a central pillar for Marinomed’s strategic development. We will also build on the promising Carragelose sales by further extending our global reach and the product line itself.”
Marinomed Biotech: weekly performance: -2.14%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (14/04/2021)

Christian Drastil: Wiener Börse Plausch

Zertifikate Party Österreich: Investieren in unsicheren Zeiten (Heike Arbter / Gunter Deuber)

Bildnachweis

Aktien auf dem Radar:Semperit, Mayr-Melnhof, CPI Europe AG, EuroTeleSites AG, Polytec Group, Kapsch TrafficCom, Österreichische Post, Wienerberger, FACC, Bajaj Mobility AG, Rosgix, Uniqa, AT&S, CA Immo, Flughafen Wien, Frequentis, Lenzing, Marinomed Biotech, Palfinger, VIG, Wolford, Wolftank-Adisa, Erste Group, Oberbank AG Stamm, RHI Magnesita, DO&CO, Amag, EVN, Telekom Austria, DAX, Fresenius Medical Care.

---